Clinical and laboratory results from adeptTM 1, a phase 2 trial investigating the use of recombinant activated FVII analogue in congenital haemophilia patients with inhibitors

de Paula, E.Kavakli, K.Mahlangu, J.Ayob, Y.Lentz, S. R.Morfini, M.Nemes, L.Salek, S. Z.Shima, M.Windyga, J.Ehrenforth, S.Andersen, H. F.Chuansumrit, A.2019-10-272019-10-2720111538-79331538-7836https://hdl.handle.net/11454/44310eninfo:eu-repo/semantics/closedAccessClinical and laboratory results from adeptTM 1, a phase 2 trial investigating the use of recombinant activated FVII analogue in congenital haemophilia patients with inhibitorsConference Object9512513WOS:000208992801423Q1